

A Study on Intrahepatic Cholestasis in Pregnancy to Evaluate Risk factors for Adverse Perinatal Outcome: An Experience from a Tertiary Care Center of East India

Subrata Das¹, Anirban Roy²

ABSTRACT

Background: Intrahepatic cholestasis (IHC) is usually a disease of late pregnancy and presented with intense pruritus with elevated liver enzymes and multifactorial in origin. Common association of IHC with meconium-stained amniotic fluid (MSAF) and adverse perinatal outcome is our area of concern. **Objectives:** The aim of the study is to know the bile acid as a predictor for adverse perinatal outcome in pregnancy complicated by IHC. **Materials and Methods:** The present observational study was conducted on 76 women, who were selected consecutively from the outpatient department of antenatal care from a tertiary care hospital of East India from January 2019 to December 2019. Women of more than 28-week gestation with pruritus of whole body and deranged liver function tests were included in the study. Descriptive analysis was used to derive mean and standard deviation from demographic data. The serum bile acid level was compared with frequencies of MSAF and adverse perinatal outcomes, level of significance was measured by calculating *P*-value. **Results:** Incidence of IHC was 3.3%, with “mean of age” and “gestational weeks” of women of 25.25 ± 3.61 years and 36.11 ± 2.75 weeks, respectively. Elevated bile acid level in relation to the presence of MSAF and each adverse perinatal outcome were highly significant (<0.01) found. The relationship was not significant (>0.05) in comparison of gestational age with MSAF. **Conclusion:** Maternal serum bile acid level can be utilized as a predictor for MSAF. However, more research is needed to predict poor fetal outcome in the pregnancy which is complicated by IHC.

KEY WORDS: Intrahepatic cholestasis in pregnancy, meconium-stained amniotic fluid, perinatal outcome, serum bile acid level.

Introduction

Intrahepatic cholestasis (IHC) is the most common hepatic disorder during pregnancy.^[1] It is reversible disorder, characterized by intense pruritus that involves whole body including palm and sole, with consequent sleep deprivation.^[2] IHC usually is found at the second or third trimester of pregnancy along with abnormally high serum aminotransferases and/or raised bile acid level.^[3,4] The marginal rise

of total bilirubin (TB) is often associated with IHC but symptoms typically resolve in 48 h postpartum but recurs on subsequent pregnancies.^[5] Ethology of exact pathology is largely unknown.^[6] Diagnosis of IHC is done by exclusions, in the absence of demonstrable hepatic or gallbladder disease. For the purpose of diagnosis, serum level of liver enzymes, bile acid, bilirubin with viral marker for hepatitis B and C assay, and upper abdominal sonography are needed. Symptoms of mild upper abdominal pain, dark colored urine, and steatorrhea were often associated and malabsorption of fat-soluble vitamins, often leading to depletion of Vitamin K-dependent clotting factors which further enhance the risks of postpartum hemorrhage (PPH).^[2]

Incidence of IHC varies worldwide, it is largely influenced by geographical and environmental

Access this article online

Quick Response Code:



Website: www.jmsh.ac.in

Doi: 10.46347/jmsh.2020.v06i03.002

¹Associate Professor, Department of Obstetrics and Gynaecology, ESI PGI MSR, ESIC Medical College and ESIC Hospital and ODC (EZ), Diamond Harbour Road, Joka, Kolkata, West Bengal, ²Associate Professor, Department of Psychiatry, Institute of Psychiatry Centre of Excellence, Institute of Post Graduate Education and Research, Kolkata, West Bengal, India

Address for correspondence:

Dr. Subrata Das, J/6, Banerjee Para, Kamdahari, Garia, Kolkata - 700 084, West Bengal, India. Phone: +91-9432326356.

E-mail: drsubrata02@gmail.com

distribution, ethnicity, genetic, and hormonal changes.^[7] Women with multiple pregnancy are more prone to develop IHC than singleton pregnancy.^[8] Highest incidence of IHC is reported from Chile (1–14%) and Poland and Spain (12%), followed by Sweden (1–1.5%), England (0.7%), and France (0.2%).^[3,4,5,7] In India, its prevalence of 1–5% is reported from different studies, the variations are mostly due to relevant geographical variation of incidence.^[1,6]

Maternal treatment with ursodeoxycholic acid (UDCA) and Vitamin K is the only available treatment option.^[9] Treatment with UDCA may cause significant relief of pruritus and improved biochemical parameters. Due to possibilities of adverse pregnancy outcome, several authors advocated for termination of pregnancy at 38 weeks or before,^[1] depending on raised bile acid levels.

In IHC, perinatal outcome can be complicated by meconium-stained amniotic fluid (MSAF), preterm birth, fetal asphyxia with low Apgar score, and increased incidences of neonatal intensive care (NICU) admission or fetal demise.^[10] There are more incidences of preterm labor, preterm premature rupture of the membranes (PPROM) and cesarean section (LUCS) are seen in IHC. Some study shows that there is significant association between markedly increased bile acid level ($>40 \mu\text{mol/L}$) and presence of MSAF.^[8,10,11] The aim of our study was to know if IHC in pregnancy increases the risk of adverse perinatal outcome.

Materials and Methods

It was an observational study conducted in a tertiary care hospital of East India during the 1-year period of January 1, 2019–December 31, 2019. Seventy-six antenatal women of more than 18 years' age and more than 28 weeks of gestation with diagnosis of IHC were subject in this study. Method for collecting data used, was complete enumeration method within the study period. IHC was diagnosed in the women with pruritus involving the whole body including palm and sole which were our study sample. The pruritus of the women was worsening at night times and associated with deranged liver function test (LFT). Women with dermatological disorders, hepatobiliary, gallbladder disease or viral hepatitis were excluded from the study. The pregnant women of IHC with singleton pregnancy, irrespective of parity, non-alcoholic and normotensives, and absence of AFP (acute fatty liver of pregnancy) or HELLP syndrome

(hemolysis, elevated liver enzymes, and low platelet count in combination) were included in the study. Studied women were treated with 600–900 mg/day of UDCA depending on the severity of symptoms (Figure 1).

All women were put under dermatological consultation to exclude the presence of dermatological disease and also upper abdominal sonography was used to rule out hepatobiliary and gallbladder pathologies. Hepatitis B surface antigen and/or antibody for hepatitis C screen positive women were also excluded from the study. The pregnancy-specific ranges as described by Bhattacharya and Kavita in their study^[12] were utilized to see the abnormalities in the LFT.

Detailed history and findings of clinical examination were recorded and women were monitored by daily fetal movement count, cardiotocography, biophysical profile, and fetal ultrasonography at usual interval for fetal surveillances. As per international guideline, women were subjected to standard treatment protocol. Data were recorded regarding maternal events of PPRM and mode of delivery (i.e., cesarean section, instrumental, or vaginal delivery) and perinatal outcome as fetal distress, Apgar score at 5th min, presence of MSAF, and NICU admission. RCOG guidelines were followed for diagnosing non-reassuring fetal heart rate pattern to document fetal distress. In our study, we considered fetal distress, low Apgar score (i.e., <7 in 5 min), preterm birth, admission in NICU, and stillbirth as adverse perinatal outcomes. These adverse perinatal outcomes were treated as unexpected outcomes in the study.

Descriptive statistics were used to analyze data for mean, standard deviation, percentage, and proportion and are presented in tabular and graphical formats. Women were labeled as IHC in studied group when one or more parameter had crossed upper margin of pregnancy specific level of LFT (12), that is, serum aspartate aminotransferase (AST) ($>59 \text{ U/L}$), alanine aminotransferase (ALT) ($>72 \text{ U/L}$), TB ($>1.3 \text{ mg/dl}$), total bile acids (TBA) ($>10 \mu\text{mol/L}$), and serum alkaline phosphatase ($>126 \text{ IU/L}$). Women were categorized in four groups on the basis of serum total bile acid level (TBA), that is, normal level ($<10 \mu\text{mol/L}$), mildly increased ($10\text{--}39.9 \mu\text{mol/L}$), moderately increased ($40\text{--}100 \mu\text{mol/L}$), and severely increased ($>100 \mu\text{mol/L}$). The normal level ($<10 \mu\text{mol/L}$) was used as reference level for




Figure 1: Flowchart of cases included in the study

comparison. The presence of MSAF was compared with the women of elevated total bile acid (TBA) and the groups of women according to gestational age. From the Pearson Chi-square test, *P*-value was calculated. *P* < 0.05 and <0.01 were considered as statistically significant and highly significant, respectively. Collected data were analyzed in the statistical software of SPSS 24th version.

Results

A total of 2303 women were delivered within our study frame in which 76 women had a diagnosis of

IHC in pregnancy. Hence, incidence was 3.3% in the study group.

According to age, women were divided into four categories. The maximum number 39 (51.3%) women were from 21 to 25 years' age group and 25 (32.9%) were from 26 to 30 years' age group. This was followed by 7 (9.2%) and 5 (6.6%) from more than 30 years and less than 20 years' age group. The mean age of women was 25.25 ± 3.61 years in the study subjects (Table 1). Mean gestational age was 36.11 ± 2.75 years among the studied women (Table 1).

With one exception, all the other women, that is, 75 (98.7%) had increased serum level of ALT and AST. The serum level of TB and alkaline phosphatase was increased to 44 (57.9%) and 54 (71%), respectively. Bile acid level of 54 (71.05%) women was higher than normal limit (Table 2).

In the present study, distribution of women with MSAF was compared with four groups of women according to bile acid level. MSAF was found in 4 (5.2%), 2 (2.6%), 8 (10.5%), and 2 (2.6%) in the four groups of women categorized as normal (<10 µmol/L), mild (10–40 µmol/L), moderate (40–100 µmol/L), and severely (>100 µmol/L) increased, respectively. Distribution of MSAF was compared with in different groups of bile acid level by Pearson Chi-squared test to derive p value. The presence of MSAF in comparison to bile acid level was seeming to be highly significant ($P < 0.01$) (Table 3 and Figure 2).

MSAF found in the women with gestational age of 28–33 weeks, 34–36 weeks, and 37–40 weeks, were 2 (2.6%), 6 (7.9%), and 8 (10.5%), respectively. The presence of MSAF was compared with the gestational age and was measured by Pearson Chi-squared test which showed $P = 0.992$. Period of gestation in comparison to MSAF was not found significant (>0.05) (Table 4).

Pregnancy complicated by fetal distress, Apgar score <7 at 5 min, admission in NICU, and intrauterine fetal death (IUFD) were found in 13 (17.1%), 8

(10.5%), 11 (14.47%), and 1 (1.31%), respectively. These findings of adverse perinatal outcomes were considered as unexpected outcomes in the study.

Women of elevated serum bile acid level compared with each adverse perinatal outcome and were measured by Pearson Chi-squared test to derive P -value. It was seen that P -value for each adverse perinatal outcome was <0.01 and seems to be highly significant (Table 5).

Among the women, 33 (43.4%) and 39 (51.3%) were delivered by cesarean section (LUCS) and 4 (5.2%) were by instrumental delivery. PPROM and PPH were found in 6 (7.9%) and 3 (3.9%) women in the study group.

Discussion

IHC in pregnancy is relatively common in obstetrics practice. Pathogenesis of IHC is thought to be multifactorial, mostly depending on genetic configuration, geographical area, environmental changes, and ethnicity. In the present study, there

Table 1: Patients according to age

Age of patients	No. of patients	Percentages	Mean±SD
<20	5	6.6	25.25±3.61
21–25	39	51.3	
26–30	25	32.9	
>30	7	9.2	
Total	76	100	




Figure 2: Meconium-stained amniotic fluid distribution according to bile acid level

Table 2: Maternal LFT Value based on maximum value recorded

Parameters	Normal value	Value > upper limit	Percentages
Bile acid (µmol/L)	0–9.9	54	71.1
Alanine aminotransferase (U/L)	0–45	75	98.7
Aspartate aminotransferase (U/L)	7–40	75	98.7
Total bilirubin (mg/dl)	0.2–1.4	44	57.9
Alkaline phosphatase (IU/L)	30–130	54	71.1

were 3.3% incidence of IHC found. It is slightly higher than those reported by other authors in similar studies. The studies of IHC were reported by Pegu *et al.*,^[1] Rook *et al.*,^[3] and Pokhrel *et al.*^[4] who were found that 2.73%, 1.9%, and 1.15%, respectively, in their study population.

In the present study, the highest number of IHC affected women was 39 (51.3%) of 21–25 year age.

In another study, the age group of 18–24 years (36%) and 21–25 years (46.67%) was affected most commonly, that was reported by Renu *et al.*^[5] and Mahajan *et al.*,^[6] respectively. These were similar to the finding found in the present study.

Mean age of women was 25.25 ± 3.61 years in the study group. In a similar study, Renu *et al.*^[6] and Celik *et al.*^[13] described that mean age of 26.42 ±

Table 3: Distribution of meconium-stained amniotic fluid (MSAF) according to bile acid level

Bile acid level		Women with meconium-stained amniotic fluid (MSAF)		
		Present	Absent	Total
Normal level (<10 μmol/L)	Count	4	18	22
	Percentage within MSAF	25.0%	30.0%	28.9%
Mildly increased (10–40 μmol/L)	Count	2	39	41
	Percentage within MSAF	12.5%	65.0%	53.9%
Moderately increased (40–100 μmol/L)	Count	8	2	10
	Percentage within MSAF	50.0%	3.3%	13.2%
Severely increased (>100 μmol/L)	Count	16	60	76
	Percentage within MSAF	12.5%	1.7%	3.9%
Total	Count	16	60	76
	Percentage within MSAF	100.0%	100.0%	100.0%

Chi-squared for trend: 31.225, DF: 3, significance level: P=0.000. MSAF: Meconium-stained amniotic fluid

Table 4: According to gestational age distribution of patients with MSAF

Category	MSAF						Mean gestational age (weeks)
	Present		Absent		Total		
	No	Percent within MSAF	No	Percent within MSAF	No	Percent	
Period of gestation (weeks)							
28–33	2	12.5	7	11.7	9	11.8	36.11 ± 2.75
34–36	6	37.5	22	36.7	28	36.8	
37–40	8	50.0	31	51.7	39	51.3	
Total (n=76)	16	21	60	78.9	76	100	

Chi-squared: 0.017, DF: 2, significance level: P=0.992. MSAF: Meconium staining of amniotic fluid

Table 5: Fetal outcome according to the presence of maternal increased bile acid

Fetal Outcome	Bile acid level			Total	Chi-square test
	Normal level (<10 μmol/L)	Bile acid level increased (≥10 μmol/L)			
Fetal distress	2	11		13	P<0.0001
Apgar at 5 min <7	1	7		8	P<0.0001
Preterm birth	5	14		19	P<0.0001
NICU admission	1	10		11	P<0.0001
Stillborn	0	0		1	-

5.79 years and 27.7 ± 5.3 years was found in their study subjects. Their findings were consistent with the finding found in the present study.

Mean gestational age was 36.11 ± 2.75 weeks in the pregnancy which is complicated by IHC within the study group. Mean age of 37 and 38 weeks was reported by Pegu *et al.*^[1] and Arthuis *et al.*^[14] in their similar study.

In our study, MSAF was compared with gestational weeks and was measured by Pearson Chi-squared test, the value of “P” was 0.992. The gestational age in comparison to MSAF was not found significant ($P > 0.05$). The studies of IHC reported by Renu *et al.*^[5] were not found in significant association ($P > 0.05$) of MSAF with weeks of gestational age at delivery in comparison with their control group. Their finding was similar to our study finding, only exception being that we had not adopted any control group.

In the present study, elevated liver enzymes levels were most commonly found but rise level of TB was less common. According to the literature review, the finding of present study was similar with the findings found by Danilidis and Tantanasis^[2] and Bhattacharrya *et al.*^[12]

In the present study, 71.1% (54) of women of study subject had elevated serum bile acid level ($>10 \mu\text{mol/L}$). It was found that increase bile acid level in maternal serum was significantly ($P < 0.01$) associated with MSAF. In a similar study reported by Geenes *et al.*,^[10] it was found that there was also significant association between increase maternal serum bile acid level and presence of MSAF. In an another study reported by Estiu *et al.*,^[11] it was also found that there was significant association in the presence of MSAF and elevated bile acid level in maternal serum. The findings of the present study were consistent and comparable with the finding.

It was found that fetal distress, low Apgar score at 5th min (<7), preterm birth (<37 weeks), admission in NICU, and stillborn were found in 17.1% (13), 10.5% (8), 25% (19), 14.5% (11), and 1.31% (1), respectively. The adverse perinatal outcomes were compared with serum bile acid level and measured by Pearson Chi-squared test and derived P-value was highly significant (<0.01). Similarly, significant (<0.01) association of adverse fetal outcome with serum bile acids was found in a study reported by Renu *et al.*^[5]

In the present study, it was also seen that preterm premature rupture of the membranes (PPROM), PPH, cesarean section (LUCS), and vaginal and instrumental delivery were 7.9%, 3.9%, 43.4%, 51.3%, and 5.3%, respectively.

In another study reported by Arthuis *et al.*^[14] on the pregnancy with IHC. In their study, they found emergency and elective caesarean section and vaginal delivery was 13.6%, 12.1% and 74.3% respectively. According to their study, preterm birth, MSF, NICU admission of newborn, and low Apgar score at 5 min (<7) were 15.7%, 18.6%, 2.9% and 2.9% respectively. All of these findings were consistent with our study findings. Only exception of excessively high PPH rate of 20.7% found in their study, may be due to the different geographical area. PPH rate was excessively high but most of the findings were consistent with the present study findings.

Pokhrel *et al.*^[4] reported in their study that MSAF, fetal distress, low Apgar score at 5th min (<7), and IUFD were 32.5%, 26.25%, 13.75%, and 6.25%, respectively. In the same study, the author also found that PPRM, PPH, and cesarean section rate (including emergency and elective indications) were 6.25%, 11.25%, and 46.25%, respectively. The study reported by Cui *et al.*^[15] compared the two subgroups of women with IHC of more than and less than serum bile acid level of $40 \mu\text{mol/L}$. They found

Table 6: Fetal outcome in different studies in percentages

Study by different authors	Fetal distress	Apgar score at 5 min <7	Preterm birth	NICU admission	IUFDD/stillborn
Renu <i>et al.</i> , 2017 ^[5]	26	-	16	20	2
Pokhrel <i>et al.</i> , 2016 ^[4]	26.25	13.75	10	48.75	6.25
Arthuis <i>et al.</i> , 2020 ^[14]	-	2.9	15.7	2.9	0
Present study	17.1	10.5	25	14.5	1.31

that there was a significant increased risk of adverse fetal outcomes in the group of more than 40 $\mu\text{mol/L}$ of serum bile acid level (Table 6).

In the present study, only one stillborn (1.31%) was delivered by a woman with severely high ($>100 \mu\text{mol/L}$) bile acid level. The study reported by Li *et al.*^[16] also found 1.2% incidence of stillborn in their study. In the same study, there was increased risk of still birth, found within the women of increased bile acid ($>40 \mu\text{mol/L}$) level. Their finding was consistent with the findings of the present study.

Due to the retrospective nature of the present study, it has certain limitations and potential for biases. The present study was conducted in a single hospital, to know the effect of increased bile acid level and its potential adverse effect on perinatal outcome, will need larger studies. More research is also required to know the ideal way of fetal monitoring and selection of optimum time regarding delivery of the baby in women.

Conclusion

Women with elevated bile acid are more prone to meconium staining of amniotic fluid and adverse perinatal outcome. Close fetal monitoring and weekly liver enzymes and bile acid assay are needed for deciding optimum delivery time to avoid adverse fetal outcome in pregnancy complicated by IHC.

References

1. Pegu B, Mehrotra M, Yadav A, Sahoo PS. Cholestasis of pregnancy: A prospective analysis from a South Andaman teaching hospital. *Int J Reprod Contracept Obstet Gynecol* 2019;8:1895-8.
2. Danilidis A, Tantanasis T. Cholestasis and pregnancy. *Eur J Inflamm* 2008;6:11-5.
3. Rook M, Vargas J, Caughey A, Bacchetti P, Rosenthal P, Bull L. Fetal outcomes in pregnancies complicated by intrahepatic cholestasis of pregnancy in a Northern California cohort. *PLoS One* 2012;7:e28343.
4. Pokhrel S, Ghimire A, Jha GS, Chhetry M, Kumar M. Feto-maternal outcomes in intrahepatic cholestasis in pregnancy in a tertiary care centre in Eastern Nepal. *J Nobel Med Coll* 2016;5:20-5.
5. Renu G, Nooren M, Abhilasha G, Neetu T, Vinita G, Rabinder I. Fetomaternal outcome in intrahepatic cholestasis of pregnancy. *Sch J Appl Med Sci* 2017;5:1789-93.
6. Mahajan N, Afzal A, Lone MI. Outcome of pregnancy complicated by obstetric cholestasis: A prospective study. *Int J Sci Study* 2017;5:271-4.
7. Sadia B, Takreem A, Munaw M. Frequency of meconium staining of amniotic fluid in intrahepatic cholestasis of pregnancy. *Kaohsiung J Med Sci* 2018;11:357-62.
8. Ovadia C, Seed PT, Sklavounos A, Geenes V, Ilio CD, Chambers J, *et al.* Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: Results of aggregate and individual patient data meta-analyses. *Lancet* 2019;393:899-909.
9. Medda S, Sengupta S, Palo U. A study of the outcome of pregnancy complicated by obstetric cholestasis. *Int J Reprod Contracept Obstet Gynecol* 2018;7:996-1001.
10. Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: A prospective population-based case-control study. *Hepatology* 2014;59:1482-91.
11. Estiu MC, Frailuna MA, Otero C, Dericco M, Williamson C, Marin JJ, *et al.* Relationship between early onset severe intrahepatic cholestasis of pregnancy and higher risk of meconium-stained fluid. *PLoS One* 2017;12:e0176504.
12. Bhattacharya A, Kavita. Feto-maternal outcome in intrahepatic cholestasis of pregnancy. *Sch J Appl Med Sci* 2016;4:3837-41. Doi:10.21276/sjams.2016.4.10.56.
13. Celik S, Caliskan CS, Celik H, Guclu M, Basbug A. Predictors of adverse perinatal outcomes in intrahepatic cholestasis of pregnancy. *Ginekol Pol* 2019;90:217-22.
14. Arthuis C, Diguisto C, Lorphelin H, Dochez V, Simon E, Perrotin F, *et al.* Perinatal outcomes of intrahepatic cholestasis during pregnancy: An 8-year case-control study. *PLoS One* 2020;15:e0228213.
15. Cui D, Zhong Y, Zhang L, Du H. Bile acid levels and risk of adverse perinatal outcomes in intrahepatic cholestasis of pregnancy: A meta-analysis. *J Obstet Gynaecol Res* 2017;43:1411-20.
16. Li L, Cong L, Chen Y, Yang Y. Risk factors for adverse fetal outcomes in patients with intrahepatic cholestasis of pregnancy. *Biomed Res* 2017;28:9193-7.

Financial Support: None; **Conflicts of Interest:** None

How to cite this article: Das S, Roy A. A Study on Intrahepatic Cholestasis in Pregnancy to Evaluate Risk factors for Adverse Perinatal Outcome: An Experience from a Tertiary Care Center of East India. *J Med Sci Health* 2020;6(3):7-13.

Date of submission: 10-07-2020

Date of review: 05-08-2020

Date of acceptance: 08-09-2020

Date of publication: 10-02-2021